google1cd7abaa8d26ae66.html

Practitioner Information


Maintrac® CTC Test

The Maintrac® CTC Count test is a simple blood test which finds every Circulating Tumour Cell present in the blood. CTCs in a 15-20mL sample of patient blood are detected and quantified. Live cells are distinguished from fragmented tumour cells and analysed. CTC-count is an independent prognostic indicator, that is, it gives an indication of the aggressiveness of a patient's cancer at the time of the test. A single CTC count test is intended as a simple baseline count. The best way to monitor cancer activity and long-term effectiveness of treatment is via a single CTC Count test every 3-6 months. Patient information hand-outs for your clinic are available upon request by phoning 1300 282 482.


PRICING

Australia: $630
New Zealand: $715

Pricing is in AUD and subject to change without notice.

Additional tests:
Customised Chemosensitivity
Companion Diagnostics
Tumour Sphere Units

ORDER A TEST

Complete instructions for ordering a test, blood sample collection and dispatch can be found here

Tests can only be ordered by registered, certified Healthcare Practitioners.

To order, please download and complete a test request, and send it to Genostics via email (office@genostics.com.au) or fax (+61 2 8088 7097).


Further reading...

Maintrac Practitioner Information

Newly added publication: Behaviour of Circulating Epithelial Tumor Cells (CETCs) and FISH (Fluorescence In Situ Hybridization) of Epidermal Growth Factor Receptor (EGFR)-gene amplification in lung cancer patients during the course of therapy ...Read this publication

Publication: Epithelial cell dissemination and readhesion: Analysis of factors contributing to metastasis formation in breast cancer (2012) ...Read this publication

Publication: An increase in cell number at the completion of therapy may develop as an indicator of early relapse (2008) ...Read this publication

Publication: Monitoring Circulating Epithelial Tumour Cells (CETC) to gauge therapy: in patients with disease progression after Tratsuzumab persisting CETC can be eliminated by combined lapatinib treatment (2008) ...Read this publication

Publication: Assessing the efficacy of targeted therapy using Circulating Epithelial Tumor Cells (CETCs): the example of SERM therapy monitoring as a unique tool to individualise therapy (2010) ...Read this publication